Radboud University Medical Center

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Radboud University Medical Center sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).

6 total trials 2 currently recruiting 3 completed early-phase tilt upper quartile by trial count

Radboud University Medical Center: 6 sponsored US clinical trials, 2 recruiting.

Radboud University Medical Center sponsors 6 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Mycobacterium Avium Complex Pulmonary Disease, with 1 trials.

Upper-quartile sponsor footprint

Radboud University Medical Center sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

What is open in the Radboud University Medical Center pipeline

2 recruiting of 6 indexed (33% open); 3 completed (50%).

Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).

Top condition: Mycobacterium Avium Complex Pulmonary Disease (1 trial), 2 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Radboud University Medical Center: open-pipeline peers nationwide

Peers matched on 6 registered trials and 33% open enrollment, not the therapeutic-area sidebar.

Radboud University Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 246810 0%20%40%60%80% Total trials Recruiting share Radboud University Medical Center23andMeAardvark TherapeuticsAbbisko Therapeutics CoAbGenomics B.V Taiwan BranchAadi BioscienceAaron CookAbivax S.A.Actuated Medical
Radboud University Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Radboud University Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 6 trials (± recruiting share)

Sponsors near 33% open enrollment (± trial volume)

What to do with this Radboud University Medical Center page

6 registered trials is a research-attention snapshot, not an endorsement of Radboud University Medical Center or any single study.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Radboud University Medical Center pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.